Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B
Solventum (NYSE: SOLV) today announced it has entered into a definitive agreement to sell its Purification & Filtration1 business to Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher") for $4.
Shares of Solventum Corp. shed 4.42% to $79.75 Friday, on what proved to be an all-around positive trading session for the ...
M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.
Solventum (NYSE:SOLV) yesterday announced fourth-quarter results that came in ahead of the consensus forecast on Wall Street.
Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...
Wells Fargo raised the firm’s price target on Solventum (SOLV) to $75 from $73 and keeps an Equal Weight rating on the shares. The Q4 beat was ...
Solventum faces significant challenges in its turnaround, including slow-growing core businesses, share loss, and margin ...
Amy Wakeham; SVP of IR; Solventum Corp. Bryan Hanson; CEO & Director; Solventum Corp. Wayde McMillan; CFO; Solventum Corp. Jason Bednar; Analyst; Piper Sandler & Co.
Piper Sandler raised the firm’s price target on Solventum (SOLV) to $84 from $75 and keeps a Neutral rating on the shares. The firm notes ...
Solventum's $4.1B divestment to Thermo Fisher enhances financial stability, boosts EPS, and strengthens its long-term growth ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback